Fig. 5
Validation of CEACAM5 as a target gene of miR-5095. (A) mRNA expression of CEACAM5 in tumor tissues (n = 408) and normal tissues (n = 211) from the GEPIA2 database. (B) Dual-luciferase reporter assay showing the binding sites and fluorescence ratio changes (ns: no significance). Statistical comparisons between groups were performed using unpaired two-tailed t-tests. CEACAM5-WT + miR-5095 mimic vs. CEACAM5-WT + NC mimic group (P < 0.0001). CEACAM5-Mut + miR-5095 mimic vs. CEACAM5-Mut + NC mimic group (P = 0.9598). (C) Western blotting assay detecting the expression of CEACAM5 in gastric cancer cells (n = 3). Statistical analysis was performed using unpaired two-tailed t-tests comparing miR-5095 mimics to mimic NC: AGS cells (P < 0.0001); HGC-27 cells (P = 0.0002). Representative image shown from three independent experiments. (D) RT-qPCR measurement of CEACAM5 expression in gastric cancer cells. Statistical analysis was performed using unpaired two-tailed t-tests comparing miR-5095 mimics to mimic NC: AGS cells (P < 0.0001); HGC-27 cells (P = 0.0001). *P < 0.05, **P < 0.01.
